Highlights Cyxone AB

Equities

CYXO

SE0007815428

Delayed Nasdaq Stockholm Other stock markets 12:56:15 14/05/2024 BST			5-day change	1st Jan Change
0.1095 ^SEK	-2.67%		+14.35%	+9.56%

04-22	Sweden's Cyxone Appoints New CEO	MT
04-22	Cyxone AB Announces Chief Executive Officer Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cyxone Enters Research Deal for Rheumatoid Arthritis Therapy	03-25	MT
Cyxone Enters Important Research Collaboration with University of Glasgow	03-25	CI
Cyxone AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-27	CI
Cyxone Reaches an Important Milestone for the Drug Candidate Rabeximod	01-15	CI
Cyxone AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/10/23	CI
Cyxone to Receive Unitary Patent in EU for T20K Drug Candidate	09/10/23	MT
Cyxone AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/08/23	CI
Cyxone Revises Strategy for Commercial Alignment Targeting Valuable Market Opportunities	29/08/23	CI
EU to Grant Cyxone Divisional Patent for Multiple Sclerosis Drug Candidate	31/05/23	MT
Cyxone AB Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Sweden’s Cyxone Secures US Patent Approval for Rabeximod Compound	09/05/23	MT
Cyxone AB Receives Notice of Allowance from the US Patent Office for the Protection of Rabeximod Compounds	02/04/23	CI
Cyxone AB Makes Significant Progress in the Manufacturing Process for Rabeximod	09/03/23	CI
Cyxone AB Reports Earnings Results for the Full Year Ended December 31, 2022	17/02/23	CI
Cyxone AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	17/02/23	CI
Cyxone Wins Georgian Nod for Phase 2b Study for Rheumatoid Arthritis Drug	09/02/23	MT
Cyxone AB Receives Ethical and Regulatory Approval from Georgia to Conduct Clinical Phase 2B Study in RA	09/02/23	CI
Cyxone Completes National Filings for Arthritis Drug Patents	06/02/23	MT
Cyxone AB Advances the Patent Portfolio for Rabeximod	06/02/23	CI
Cyxone Receives Ethical and Regulatory Approval from Hungary to Start Clinical Phase 2b Study in RA	01/12/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cyxone AB

Equities

CYXO

SE0007815428

Highlights

Filters